Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma

Exelixis Inc EXEL has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc PFE for the ongoing Phase 1b dose-escalation study STELLAR-001.

  • The study will add three new cohorts that will evaluate the safety and tolerability of Exelixis' XL092, in combination with Merck/Pfizer's Bavencio (avelumab), in patients with locally advanced or metastatic urothelial carcinoma (UC).
  • Exelixis is sponsoring the STELLAR-001 trial, and Merck KGaA and Pfizer will provide avelumab for use in the trial.
  • Additional expansion cohorts include maintenance therapy, patients who have progressed following treatment with an immune checkpoint inhibitor, and patients previously treated with platinum-containing chemotherapy.
  • XL092 is an investigational, next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in the growth and spread of cancer.
  • Price Action: EXEL shares are trading 0.86% higher at $23.35 in premarket trading on the last check Thursday.
Loading...
Loading...
EXEL Logo
EXELExelixis Inc
$43.251.53%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
95.34
Growth
Not Available
Quality
87.02
Value
54.78
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...